Evidence map›Paper›PMID 40417706›Full record

ArticleJournal of blood medicine2025

Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.

Ana Marco-Rico, José Manuel Calvo-Villas, Francisco-José López-Jaime, Mariana Canaro Hirnyk, Maria Del Mar Nieto Hernández, Sonia Herrero Martín, Laura Entrena-Ureña, Shally Marcellini-Antonio, Bolívar L Díaz-Jordán, Sergio Jurado-Herrera and 5 more

Abstract read
In one paragraph

Article in Journal of blood medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Milds Matter-Feasibility of Emicizumab Prophylaxis in Mild Hemophilia.Haemophilia : the official journal of the World Federation of Hemophilia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ana Marco-RicoHematology Department, Hospital General Universitario Dr. Balmis-ISABIAL, Alicante, Spain.ORCID 0000-0002-7971-6591
José Manuel Calvo-VillasHematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Francisco-José López-JaimeHematology Department, Hospital Regional Universitario de Málaga-IBIMA, Málaga, Spain.
Mariana Canaro HirnykHematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
Maria Del Mar Nieto HernándezHematology Department, Complejo Hospitalario de Jaén, Jaén, Spain.
Sonia Herrero MartínHematology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Laura Entrena-UreñaHematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Shally Marcellini-AntonioHematology Department, Complejo Asistencial de Segovia, Segovia, Spain.
Bolívar L Díaz-JordánHematology Department, Hospital General de Valdepeñas, Ciudad Real, Spain.
Sergio Jurado-HerreraHematology Department, Hospital Universitario Torrecárdenas, Almería, Spain.
Noelia Florencia Pérez-GonzálezHematology Department, Hospital Universitario Torrecárdenas, Almería, Spain.
Covadonga García-DíazHematology Department, Hospital Universitario de Burgos, Burgos, Spain.
Faustino García-CandelHematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Ihosvany Fernández-BelloHematology Department, Hospital General Universitario Dr. Balmis-ISABIAL, Alicante, Spain.
Pascual Marco-VeraHematology Department, Hospital General Universitario Dr. Balmis-ISABIAL, Alicante, Spain.ORCID 0000-0002-3412-7566

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients with non-severe hemophilia A (PwnSHA) may be at risk for joint damage (JD), yet data remain scarce. Our aim was to evaluate the joint condition in PwnSHA in a real-world setting. Patients and Methods: A nationwide, multicenter, cross-sectional study was conducted. To mitigate the impact of discrepancies between factor VIII (FVIII) assays, baseline FVIII levels were determined using chromogenic and one-step clotting assays. Mutation in F8 gene, baseline FVIII levels, thrombin generation and age were assessed. The joint condition was described using the HEAD-US score by trained specialists at each participating hospital. Results: One hundred and twenty-four patients were recruited, 84 of them with an available HEAD-US evaluation, who were finally included in our analysis. The median age was 38.4 years (18.3-48.5). Twenty percent (16/84) had moderate hemophilia (MoH) with FVIII levels of 4.0 IU/dL (2.6-4.6), and 80% (68/84) had mild hemophilia (MiH) with FVIII levels of 14.8 IU/dL (10.4-19.9), (p< 0.001). JD (HEAD-US>0) was observed in 50% (8/16) of MoH patients (HEAD-US= 6.5 [5.5-8.5]) and in 40% (27/68) of those with MiH (HEAD-US= 3.0 [2.0-6.5]), p=0.198. In the moderate group, JD was primarily observed in ankles (44%), while in the MiH group, knees were the most affected (31%). MoH patients reported a hypocoagulable thrombin generation profile compared to MiH patients (p<0.05). Conclusion: Near half of PwnSHA had JD. A worse joint health and a lower thrombin generation was observed in MoH population. These patients can benefit from an early prophylaxis and prevent further joint deterioration. Future research should explore additional variables that might influence joint condition.

Indexed as

assay discrepanciesHEAD-USjoint damagemild hemophilia Amoderate hemophilia Areal-world data

Identifiers

PMID40417706
PMCPMC12101468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.